This positive PMDA feedback significantly de-risks the regulatory pathway for CardiAMP in Japan, a key market. Traders should monitor the release of PMDA meeting minutes for a potential filing timeline and watch for updates on commercial planning. Given BioCardia's small $13M market cap, any progress toward approval could drive substantial upside.
Price Chart
Executive Summary
BioCardia announced a positive outcome from its regulatory consultation with Japan's PMDA, which indicated that existing clinical data for its CardiAMP Cell Therapy is likely sufficient to support market clearance in Japan for ischemic heart failure. The company awaits formal minutes and a timeline for potential filing, marking a significant regulatory milestone for its lead therapy.
Key Facts
- Japan's PMDA determined that clinical safety and efficacy data for CardiAMP Cell Therapy is likely sufficient for market clearance in ischemic heart failure.
- PMDA accepted foreign clinical data from U.S. trials and aligned on indications, market introduction approach, and post-marketing study requirements.
- CardiAMP has FDA Breakthrough Therapy designation and is a minimally invasive, autologous cell therapy delivered via catheter.
- Therapy is supported by the Maryland Stem Cell Research Fund and reimbursed by CMS in the U.S.
- Company awaits PMDA meeting minutes for detailed feedback and potential filing timeline.
Financial Impact
Potential near-term commercial opportunity in Japan; deal value or revenue impact not disclosed but represents a major de-risking event for the therapy's regulatory path.
Risk Factors
- Final PMDA decision and formal filing timeline are pending; clearance is not yet guaranteed.
- Company has limited liquidity and may need to raise additional capital, which could dilute shareholders.
- Commercial execution in Japan will require partnerships or infrastructure not currently detailed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9068 (+1.04%) |
Oct 19, 2026 8d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9068 (+0.76%) |
Oct 7, 2026 20d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9068 (−16.81%) |
Oct 1, 2026 26d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9068 (−11.10%) |
Oct 1, 2026 26d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9068 (−11.10%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9068 (−13.64%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9068 (−13.64%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9068 (−17.56%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9068 (−14.45%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9068 (−4.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers